Technology area: Biotechnology & Pharmaceuticals
13 pending office actions • 11 art units • 12 examiners • 0 of 13 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
UNIVERSITE PARIS CITE has 12 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 11 examiners across 10 art units, showing a distributed prosecution profile with some repeated assignments.
LUSI, ELLIS FOLLETT handles 2 pending matters, the largest stated examiner concentration. The rest of the docket is spread among other examiners, making centralized tracking important while limiting the value of a single examiner-centered strategy.
Counsel can use the art-unit groupings to compare office-action themes and coordinate related applications. Each response should still account for the separate examiner record and the specific technical issues presented.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (15%) |
| §103 only | 2 (15%) |
| §112 only | 1 (8%) |
| Double-patenting only | 1 (8%) |
| Multi-statute (no §101) | 7 (54%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LUSI, ELLIS FOLLETT | 2 | 64.0% | +53.7% |
| GROSS, JASON PATRICK | 1 | 64.0% | +43.3% |
| HUTTER, GILLIAN A | 1 | 54.5% | +46.0% |
| JAUHARI, SACHI | 1 | 60.0% | +80.0% |
| CONSTANTINE, CHARLES Z | 1 | 59.0% | +49.3% |
| BARRON, SEAN C | 1 | 52.7% | +30.4% |
| MCDOWELL, BRIAN E | 1 | 74.0% | +31.0% |
| QIAN, CELINE X | 1 | 47.5% | +17.2% |
| OSENBAUGH-STEWART, ELIZA W | 1 | 73.0% | +16.8% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18247945 | GDF3 AS BIOMARKER AND BIOTARGET IN POST-ISCHEMIC CARDIAC REMODELING | LUSI, ELLIS FOLLETT | 103d overdue |
| 18273252 | DEVICE FOR MEASURING AND/OR MODIFYING A SURFACE | OSENBAUGH-STEWART, ELIZA W | 13d |
| 18700200 | GIANT ORGANELLES RECOVERY AND USE THEREOF | BARRON, SEAN C | 21d |
| 18032817 | METHOD FOR EVALUATING THE MECHANOBIOLOGICAL PROPERTIES OF A CELL ELEMENT | LUSI, ELLIS FOLLETT | 34d |
| 18857856 | NEW FORMULATION OF ATROPINE | HUTTER, GILLIAN A | — |
| 18684600 | NOVEL SEROTONIN DERIVATIVES AND THEIR USES FOR TREATING IRON-ASSOCIATED DISORDERS | MCDOWELL, BRIAN E | — |
| 18684010 | METHODS FOR THE TREATMENT OF OCULAR ROSACEA | QIAN, CELINE X | — |
| 18268450 | MIRNA COMPOSITION COMPRISING 11 SPECIFIC MIRNAS AND ITS USE IN THE TREATMENT OF CANCER | VANHORN, ABIGAIL LOUISE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18247945 | GDF3 AS BIOMARKER AND BIOTARGET IN POST-ISCHEMIC CARDIAC REMODELING | LUSI, ELLIS FOLLETT | 103d overdue |
| 18273252 | DEVICE FOR MEASURING AND/OR MODIFYING A SURFACE | OSENBAUGH-STEWART, ELIZA W | 13d |
| 18700200 | GIANT ORGANELLES RECOVERY AND USE THEREOF | BARRON, SEAN C | 21d |
| 18032817 | METHOD FOR EVALUATING THE MECHANOBIOLOGICAL PROPERTIES OF A CELL ELEMENT | LUSI, ELLIS FOLLETT | 34d |
| 19078397 | Efficient Magnetic Resonance Elastography using Interleaved Motion Encoding | GROSS, JASON PATRICK | — |
| 18857856 | NEW FORMULATION OF ATROPINE | HUTTER, GILLIAN A | — |
| 18730927 | COMPOUND FOR USE IN PREVENTING AND/OR TREATING AN INFECTION CAUSED BY SARS-COV-2 | JAUHARI, SACHI | — |
| 18725322 | METHODS OF INDUCING CELL DEATH OF A POPULATION OF SOLID TUMOR CELLS | CONSTANTINE, CHARLES Z | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 1677 | 2 |
| 3797 | 1 |
| 1625 | 1 |
| 1657 | 1 |
| 1653 | 1 |
| 1624 | 1 |
| 1637 | 1 |
| 2881 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19078397 | Efficient Magnetic Resonance Elastography using Interleaved Motion Encoding | GROSS, JASON PATRICK | 3797 | §103 | Non-Final OA | — | Pending | Mar 13, 2025 |
| 18857856 | NEW FORMULATION OF ATROPINE | HUTTER, GILLIAN A | 1625 | §102§103 | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18730927 | COMPOUND FOR USE IN PREVENTING AND/OR TREATING AN INFECTION CAUSED BY SARS-COV-2 | JAUHARI, SACHI | 1654 | §103Other | Non-Final OA | — | Pending | Jul 22, 2024 |
| 18725322 | METHODS OF INDUCING CELL DEATH OF A POPULATION OF SOLID TUMOR CELLS | CONSTANTINE, CHARLES Z | 1657 | §112 | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18700200 | GIANT ORGANELLES RECOVERY AND USE THEREOF | BARRON, SEAN C | 1653 | §102§103 | Final Rejection | 21d | Pending | Apr 10, 2024 |
| 18684600 | NOVEL SEROTONIN DERIVATIVES AND THEIR USES FOR TREATING IRON-ASSOCIATED DISORDERS | MCDOWELL, BRIAN E | 1624 | §102§112 | Final Rejection | — | Pending | Feb 16, 2024 |
| 18684010 | METHODS FOR THE TREATMENT OF OCULAR ROSACEA | QIAN, CELINE X | 1637 | §102§112 | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18273252 | DEVICE FOR MEASURING AND/OR MODIFYING A SURFACE | OSENBAUGH-STEWART, ELIZA W | 2881 | §102§103§112 | Non-Final OA | 13d | Pending | Jul 19, 2023 |
| 18268450 | MIRNA COMPOSITION COMPRISING 11 SPECIFIC MIRNAS AND ITS USE IN THE TREATMENT OF CANCER | VANHORN, ABIGAIL LOUISE | 1636 | §101§102§103§112 | Final Rejection | — | Pending | Jun 20, 2023 |
| 18032817 | METHOD FOR EVALUATING THE MECHANOBIOLOGICAL PROPERTIES OF A CELL ELEMENT | LUSI, ELLIS FOLLETT | 1677 | §103§112 | Non-Final OA | 34d | Pending | Apr 20, 2023 |
| 18247945 | GDF3 AS BIOMARKER AND BIOTARGET IN POST-ISCHEMIC CARDIAC REMODELING | LUSI, ELLIS FOLLETT | 1677 | §101§102§103§112 | Non-Final OA | 103d overdue | Pending | Apr 05, 2023 |
| 18003999 | METHODS FOR PREDICTING THE RISK OF RECURRENCE AND/OR DEATH OF PATIENTS SUFFERING FROM A SOLID CANCER AFTER PREOPERATIVE ADJUVANT THERAPY AND RADICAL SURGERY | DENT, ALANA HARRIS | 1643 | DP | Final Rejection | 16d | Pending | Dec 30, 2022 |
| 17904529 | OPTIMIZATION OF PEPTIDE-MELANIN BINDING | D' AMBROSIO, THEA | 1654 | §102§103§112 | Non-Final OA | — | Pending | Aug 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITE PARIS CITE has 13 pending office actions as of October 2026, spread across 11 art units and 12 examiners.
Ellis Follett Lusi has the most, with 2 of UNIVERSITE PARIS CITE's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
